Norton Rose Fulbright advises Shionogi on joint venture with Purdue Pharma
December 21, 2016
Norton Rose Fulbright advised Shionogi & Co., Ltd., a drug-discovery based pharmaceutical company dedicated to developing medicines that protect the health and well-being of patients, and Purdue Pharma L.P., a privately held pharmaceutical company founded by physicians over 60 years ago, distinguished by its pioneering research, products and medical programs directed toward alleviating pain, yesterday announced the establishment of an alliance for the joint US launch and commercialization of Symproic® (naldemedine).
Symproic®, a novel peripherally acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in adults with chronic non-cancer pain, is currently under review at the US Food and Drug Administration. The target action date for Symproic® under the Prescription Drug User Fee Act is Mar. 23, 2017.
In this alliance, Purdue’s leading expertise in the care of patients with pain will be combined with Shionogi’s knowledge as the inventor and global developer of naldemedine. Purdue and Shionogi will jointly launch and commercialize Symproic®, including a comprehensive collaboration on all aspects of strategy, sales and other activities.
Andres Liivak (New York) led the team representing Shionogi. Additional lawyers who provided support included Tom Owens (Austin), Blake Walsh (Washington, DC), Robin Adelstein (New York), Mark Faccenda (Washington, DC) and Chen Zhang (Houston).